Long-term risk of psychiatric disorder and psychotropic prescription after SARS-CoV-2 infection among UK general population

Yunhe Wang, Binbin Su, Junqing Xie (), Clemente Garcia-Rizo and Daniel Prieto-Alhambra
Additional contact information
Yunhe Wang: University of Oxford
Binbin Su: Chinese Academy of Medical Sciences/Peking Union Medical College
Junqing Xie: University of Oxford
Clemente Garcia-Rizo: Universitat de Barcelona (UB)
Daniel Prieto-Alhambra: University of Oxford

Nature Human Behaviour, 2024, vol. 8, issue 6, 1076-1087

Abstract: Abstract Despite evidence indicating increased risk of psychiatric issues among COVID-19 survivors, questions persist about long-term mental health outcomes and the protective effect of vaccination. Using UK Biobank data, three cohorts were constructed: SARS-CoV-2 infection (n = 26,101), contemporary control with no evidence of infection (n = 380,337) and historical control predating the pandemic (n = 390,621). Compared with contemporary controls, infected participants had higher subsequent risks of incident mental health at 1 year (hazard ratio (HR): 1.54, 95% CI 1.42–1.67; P = 1.70 × 10−24; difference in incidence rate: 27.36, 95% CI 21.16–34.10 per 1,000 person-years), including psychotic, mood, anxiety, alcohol use and sleep disorders, and prescriptions for antipsychotics, antidepressants, benzodiazepines, mood stabilizers and opioids. Risks were higher for hospitalized individuals (2.17, 1.70–2.78; P = 5.80 × 10−10) than those not hospitalized (1.41, 1.30–1.53; P = 1.46 × 10−16), and were reduced in fully vaccinated people (0.97, 0.80–1.19; P = 0.799) compared with non-vaccinated or partially vaccinated individuals (1.64, 1.49–1.79; P = 4.95 × 10−26). Breakthrough infections showed similar risk of psychiatric diagnosis (0.91, 0.78–1.07; P = 0.278) but increased prescription risk (1.42, 1.00–2.02; P = 0.053) compared with uninfected controls. Early identification and treatment of psychiatric disorders in COVID-19 survivors, especially those severely affected or unvaccinated, should be a priority in the management of long COVID. With the accumulation of breakthrough infections in the post-pandemic era, the findings highlight the need for continued optimization of strategies to foster resilience and prevent escalation of subclinical mental health symptoms to severe disorders.

Date: 2024
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41562-024-01853-4 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nathum:v:8:y:2024:i:6:d:10.1038_s41562-024-01853-4

Ordering information: This journal article can be ordered from
https://www.nature.com/nathumbehav/

DOI: 10.1038/s41562-024-01853-4

Access Statistics for this article

Nature Human Behaviour is currently edited by Stavroula Kousta

More articles in Nature Human Behaviour from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().